WO2008115390A3 - Methods of using defensins to treat diabetes - Google Patents

Methods of using defensins to treat diabetes Download PDF

Info

Publication number
WO2008115390A3
WO2008115390A3 PCT/US2008/003316 US2008003316W WO2008115390A3 WO 2008115390 A3 WO2008115390 A3 WO 2008115390A3 US 2008003316 W US2008003316 W US 2008003316W WO 2008115390 A3 WO2008115390 A3 WO 2008115390A3
Authority
WO
WIPO (PCT)
Prior art keywords
defensins
methods
treat diabetes
present
metabolic disorders
Prior art date
Application number
PCT/US2008/003316
Other languages
French (fr)
Other versions
WO2008115390A2 (en
Inventor
Wenhong Cao
Original Assignee
Hamner Inst For Health Science
Wenhong Cao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamner Inst For Health Science, Wenhong Cao filed Critical Hamner Inst For Health Science
Publication of WO2008115390A2 publication Critical patent/WO2008115390A2/en
Publication of WO2008115390A3 publication Critical patent/WO2008115390A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of regulating metabolic disorders including administering to a subject in need thereof an effective amount of a defensin. Metabolic disorders that can be regulated according to the present invention include diabetes, hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia and hyperlipoproteinemia.
PCT/US2008/003316 2007-03-16 2008-03-12 Methods of using defensins to treat diabetes WO2008115390A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89521607P 2007-03-16 2007-03-16
US60/895,216 2007-03-16

Publications (2)

Publication Number Publication Date
WO2008115390A2 WO2008115390A2 (en) 2008-09-25
WO2008115390A3 true WO2008115390A3 (en) 2008-12-24

Family

ID=39766659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003316 WO2008115390A2 (en) 2007-03-16 2008-03-12 Methods of using defensins to treat diabetes

Country Status (1)

Country Link
WO (1) WO2008115390A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193441A2 (en) * 2015-06-03 2016-12-08 Takara Bio Europe Ab Maturation of mammalian hepatocytes
JP6890135B2 (en) * 2016-01-26 2021-06-18 ディフェンシン セラピューティクス エーピーエス Methods for regulating the gut microbiota
BR112018071972A2 (en) * 2016-04-29 2019-02-26 Defensin Therapeutics Aps methods for treating or preventing a liver disease or disorder, for treating liver cancer, and for treating inflammation in the liver, biliary tract or pancreas of a mammalian alpha-defensin and / or ss-defensin and / or a catelicidine and / or a glp-1 analog, and use thereof.
AU2017376400A1 (en) 2016-12-13 2019-06-20 Novozymes A/S Methods for treating inflammatory conditions of the lungs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063219A1 (en) * 2003-01-13 2004-07-29 Ares Trading S.A. Defensin protins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063219A1 (en) * 2003-01-13 2004-07-29 Ares Trading S.A. Defensin protins

Also Published As

Publication number Publication date
WO2008115390A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2007112069A3 (en) Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
IL246402A (en) Therapeutic agent for treating obesity, diabetes and diseases associated with impaired glucose tolerance
WO2007109135A3 (en) Neuromedin u receptor agonists and uses thereof
EP1841781A4 (en) Use of il-22 for the treatment of conditions of metabolic disorders
MX2009011359A (en) Pyrimidinone derivatives and methods of use thereof.
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
MX362503B (en) Lixisenatide as add-on therapy to basal insulin in type 2 diabetes.
WO2010043566A3 (en) Combination of an insulin and a glp-1 agonist
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
WO2013186240A3 (en) Exendin-4 peptide analogues
WO2012054526A3 (en) Chemosensory receptor ligand-based therapies
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
CL2011003095A1 (en) Cyclic peptide specific for melanocortin receptors; use to treat diabetes, obesity, overweight and / or diseases, disorders and / or conditions associated with obesity and / or overweight, including insulin resistance.
WO2008077092A3 (en) Combined effects of topiramate and ondansetron on alcohol consumption
WO2011092473A8 (en) Novel compounds and their effects on feeding behaviour
WO2009143387A3 (en) Modulation of smrt expression
EA033397B1 (en) Method of treating prediabetes, type 1 or type 2 diabetes mellitus or improving glycemic control in a patient with said disorders
EP2579876A4 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2010123838A3 (en) Novel amide and amidine derivatives and uses thereof
EP2646032A4 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes
WO2008115390A3 (en) Methods of using defensins to treat diabetes
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742062

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742062

Country of ref document: EP

Kind code of ref document: A2